Abstract: Purpose/Background: Personalized (N-of-1) trials are single-patient, crossover-design trials that may be useful for personalizing the selection of depression treatments. We conducted a systematic review of published N-of-1 trials for depression to determine the feasibility and suitability of this methodology for personalizing depression care.
M
ajor depression is one of the most common psychiatric conditions, affecting approximately 1 in 6 individuals over the course of their lifetime. 1 Depression is also a leading cause of disability worldwide. 2 Depression increases risk of suicide, impairs quality of life, and decreases work productivity. [3] [4] [5] Unfortunately, approximately 40% of patients do not respond to first-line depression treatments such as antidepressants or psychotherapy. 6, 7 Although specific antidepressants have similar efficacy on average, there are large interindividual differences in how patients respond to specific depression treatments, both with respect to benefits and harms. 8 Many patients drop out of treatment after an initial treatment failure. 9 Yet, studies show that up to 50% of patients who fail to respond to a first depression treatment can obtain benefit after switching to a second treatment. 10 This suggests that improving the selection of the initial depression treatment can greatly benefit patients suffering from depression.
Personalized medicine seeks to optimize the selection of treatments based on a patient's personal characteristics. In the field of depression, despite some promising data, there are few examples of personal characteristics or biomarkers that can reliably predict treatment responsiveness at the individual level. For example, although cytochrome P450 system 2D6 polymorphisms have been associated with poor metabolism and adverse effects from antidepressants among some patients, evidence for routinely screening for these polymorphisms remains lacking. 11, 12 More recently, brain positron emission tomography neuroimaging findings have predicted whether patients benefit from antidepressant versus cognitive behavioral therapy. 13 Yet, this finding remains to be replicated or applied to clinical settings. 14 A recent systematic review seeking to identify characteristics that could be used to predict treatment response concluded that there were few robust predictors available. 15 Another potential approach to personalizing depression treatments is the use of personalized trials, commonly referred to as N-of-1 trials in the research literature. N-of-1 trials lie within the family of single-case-design studies. 16 The defining characteristic of an N-of-1 trial is the prospective crossover design (eg, A-B-A-B) within an individual participant in which 1 period (A) is the treatment being studied, and another period (B) is the treatment being compared. 17 The use of multiple crossovers increases confidence in the reliability of results and is a required feature of N-of-1 trials according to some expert classifications. 17 Yet, even simple A-B crossover designs are considered N-of-1 trials by other experts so long as the primary goal is to inform treatment selection among individual patients. 18 Another key characteristic of N-of-1 trials is the systematic collection of data on treatment effects including patient-important outcomes. Although the primary focus of N-of-1 trials is on the individual patient, data from a series of N-of-1 trials can be pooled to generate an understanding of population-level treatment effects. [19] [20] [21] N-of-1 trials are ideally suited to clinical problems for which there is uncertainty or clinical equipoise about the best treatment for an individual patient and for which there are reliable measures for assessing treatment effects. Further, they are well suited to comparing treatments such as antidepressants that are expected to have heterogeneous effects both in terms of benefits and adverse effects among different patients such that there is value in learning which treatment is best for the individual. Finally, N-of-1 trials are suitable for chronic conditions that have readily measurable symptoms (see Table 1 for a summary of conditions under which N-of-1 trials are suitable). 22 N-of-1 trials differ from the usual "trial-of-therapy" approach that is the mainstay of clinical practice. In the "trial of therapy" approach, patients are started on a treatment, and the patient's status is compared from before to after starting the treatment in an informal manner. This approach is susceptible to a biased understanding of treatment effects that are due to recall bias, expectancy effects, and time effects. N-of-1 trials improve upon the "trial of therapy" approach in that patients compare 2 or more treatments at the outset (or a treatment with a placebo), data on treatment effects are systematically collected, and data are rigorously analyzed to empirically inform the selection of treatments (Fig. 1) . 23 Rigorous N-of-1 trials can also involve randomization of the treatment sequence and blinding of treatments. These design features can be used to minimize expectancy effects that arise when treatments are provided open label. Balanced treatment sequences (eg, A-B-B-A) can be used in place of randomization to reduce the potential for time effects to lead to a biased understanding of treatment effects. Based on these strengths, N-of-1 trials are considered to be among the strongest designs for making individual decisions about a patient's treatment selection and are considered level 1 evidence by the Oxford Center for Evidence Based Medicine. 24 The prototypical N-of-1 trial is also distinct from conventional research designs in that the treatment options and monitoring parameters can be customized according to patient preferences, and results can be shared with patients at the end of the trial to maximize shared decision making pertaining to treatment selection.
Depression may be a suitable candidate for personalized trials, as there is substantial heterogeneity of treatment effects for many established depression treatments and uncertainty about which treatment is best for each patient; there are also emerging and off-label depression treatments that have potential benefit for individual patients but lack large randomized clinical trials across many patient populations; depressive symptoms can be assessed regularly with valid tools; and depression is frequently chronic and slowly progressing. On the other hand, the suitability of N-of-1 trials for depression may be limited as some depression treatments have a relatively long onset of action (eg, serotoninspecific receptor inhibitors can take weeks to achieve maximal onset of action), and others are intended to have irreversible or long-lasting effects (eg, insight-oriented psychotherapy).
To determine if the personalized N-of-1 trial approach would be a useful alternative to the current predominant trial-of-therapy approach to selecting depression treatments, we conducted a systematic review of N-of-1 trials for depression. A prior systematic review reviewed the characteristics and treatment implications of N-of-1 trials published in the medical literature. 18 This review, however, was conducted in 2010, did not include search terms targeted to identifying N-of-1 trials for depression, and did not assess study design characteristics relevant to assessing the feasibility of N-of-1 trials for depression. Further, the search strategy limited itself to N-of-1 trials with randomized treatment assignments and may have excluded N-of-1 trials with nonrandomized, balanced sequence designs. We aimed to determine the number, types, and quality of N-of-1 trials relevant to depression. Review of these outcomes was intended to provide clinicians and researchers with the information needed to determine the feasibility and suitability of pursuing N-of-1 trials to personalize the selection of depression treatments for individual patients.
MATERIALS AND METHODS
The protocol for this systematic review was registered in PROSPERO, a publicly available international database of prospectively registered systematic reviews, prior to conducting the • Patients, health care providers, and health system willing to engage in N-of-1 trials
Step 1 involves customizing the N-of-1 trial according to patient and clinician preferences.
Step 2 involves patients tracking treatment effects via diaries or mobile health devices.
Step 3 involves statistically analyzing and visualizing results.
Step 4 involves treatment selection via shared decision making informed by patient data.
review. 25 The reporting of this review conforms to Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. 26 This study was supported by funding from the National Institutes of Health and the Patient-Centered Outcomes Research Institute.
Study Selection
Studies were eligible for inclusion if they met the following criteria: (1) population: humans with elevated depressive symptoms; (2) interventions: all pharmacological and nonpharmacological treatments for depression (ie, no restrictions on interventions); (3) types of studies: single-case research designs that involved at least 1 crossover between treatment A and treatment B; (4) comparator/control: placebo or active treatment control; and (5) outcome: depressive symptoms had to be included. There was no requirement for interventions to be administered in a blinded or randomized fashion or to include multiple crossovers. Studies were excluded if they did not contain sufficient design detail to determine eligibility (ie, they consisted primarily of methods and review without presentation of any data or results from an N-of-1 trial) and/or were not available in English.
Data Sources
Potentially relevant articles were identified by searching the following biomedical electronic databases from database inception to October 11, 2016: Ovid MEDLINE, EMBASE, the Cochrane Library (all databases), CINAHL, and PsycINFO. All relevant subject headings and free-text terms were used to represent N-of-1 randomized trials and depression. Terms for MEDLINE included: n-of-1.tw OR ((individual or single) adj (patient$ or participant$ or subject$ or case$)).tw. OR ipd.tw AND exp depressive disorders/OR Depression/OR anhedonia/OR (depress$ or anhedoni$).tw. Additional terms were applied to identify clinical trials. These terms were adapted for the other databases. Ongoing studies were also sought through Clinicaltrials.gov and the World Health Organization International Clinical Trials Registry Platform. Additional records were identified by scanning the reference lists of relevant studies and reviews, by using the Similar Articles feature in PubMed, and by using the Cited Reference Search in Scopus.
Study Selection
Two reviewers (M.H., L.F.) independently screened titles and abstracts of all the retrieved bibliographic records. Full texts of potentially eligible records passing the title and abstract screening level were retrieved and examined independently by the 2 reviewers according to the previously mentioned eligibility criteria. A third reviewer (I.M.K.) adjudicated disagreements at both screening levels (title/abstract and full text.)
Data Extraction
Two investigators (M.H., B.K.) extracted all data, with disagreements again resolved through consensus with a third investigator (I.M.K.) present. The following information was extracted, if present: publication year; country where N-of-1 trial was conducted; trial funding; institutional review board (IRB) approval; trial setting; rationale for using an N-of-1 approach; participant eligibility criteria and characteristics; trial design including treatments compared, treatment sequence, duration, randomization, allocation, blinding, and use of washout periods; depressive symptom measures and frequency of measurement; method of analysis including sample size determination, responder definition; N-of-1 trial results (number of participants enrolled, number and sequence of periods completed, losses or exclusion of participations after treatment assignment, number of periods analyzed, number of trials for which data were synthesized); and impact of N-of-1 trial on subsequent treatment. Finally, study quality was rated as low or high using criteria established by the CONSORT Extension for Reporting N-of-1 Trials (CENT). 27 
Analysis
The findings of the various studies are summarized in Table 2 . As the studies did not report on patient or clinician satisfaction with the N-of-1 trial design, and as treatment comparisons and study populations were not similar across trials, we did not pool results between studies.
Role of the Funding Source
The funding source had no role in the design; in the collection, analysis, or interpretation of data; or in the writing of the report or decision to submit for publication.
RESULTS
Of the 2588 nonduplicate articles identified by our search, 5 met our full inclusion criteria. [28] [29] [30] [31] [32] One study compared the effectiveness of an antidepressant (amitriptyline) with placebo in a patient with multiple somatic symptoms, but this study was excluded because the patient was not being treated for depression, and depressive symptoms were not assessed during the trial. 33 Another study compared imipramine with placebo in a patient with intellectual disability with symptoms of distress, but was excluded because depressive symptoms were not directly assessed. 34 The study selection process with reasons for exclusions is presented in Figure 2 .
Trial Setting
Articles were published from 1986 to 2016 and were conducted in the United States, Germany, Australia, and the Netherlands. Trial settings included nursing homes, foster care with on-site nurse, inpatient psychiatry unit, and outpatient psychiatry clinics.
Rationale for N-of-1 Trials
In 1 study, the goal was to compare the effect of D-amphetamine with methylphenidate and to determine the extent of heterogeneity of treatment effect in a series of patients. 29 In another study, the goal was to personalize the selection of a treatment (methylphenidate) in a special population (depressed geriatric nursing home patients) that was excluded from prior randomized trials and in whom there were expectations of substantial interindividual differences in harms and benefits. 31 In 1 study, the goals were to compare the effectiveness of an off-label use of an antipsychotic (sulpiride) with placebo for treatment of chronic depression and to determine the extent of heterogeneity of treatment effect across a series of patients. 30 In the next study, the goals were determine the best dose of an off-label treatment with placebo and to determine the extent of heterogeneity between patients in a series of patients. 32 In the final study, the goal was to compare the effectiveness of a pharmacologic treatment with placebo in a patient with human immunodeficiency virus (HIV)-associated encephalopathy likely to have been excluded from conventional randomized controlled trials (RCTs). 28 
Ethics and Funding Support
Institutional review board approval was explicitly reported as being obtained for 2 of the N-of-1 studies; informed consent without explicitly mentioning IRB review was mentioned in 2 others; and 1 study did not comment on informed consent. Two studies 
Participants
Studies enrolled between 1 and 18 patients in their N-of-1 protocol. There was significant heterogeneity in patient characteristics. One study enrolled a single cognitively impaired, depressed patient with HIV-associated encephalopathy. 28 Another study enrolled 3 nursing home-residing geriatric patients, aged 78 to 81 years. 31 Another study enrolled 18 depressed patients, aged 22 to 45 years, admitted to an inpatient psychiatry unit. 29 Two studies enrolled treatment-resistant depressed patients with insufficient therapeutic response to at least 1 trial of an antidepressant during the current depressive episode (n = 15 and n = 10). 30, 32 Only 1 of the studies explicitly reported how potential participants were recruited, and none reported how many declined to participate after learning about the study protocol. 32 
Trial Design Features
Active treatments assessed in the studies included methylphenidate, D-amphetamine, ketamine, and sulpiride. Three studies included an inactive placebo. 28, 30, 31 One study included a sham treatment (midazolam for comparison with ketamine) 32 ; this study compared different doses of the same treatment to one another and to the sham. All studies were double-blind. Treatment periods ranged from 1 day to 6 weeks. Washout periods ranged from less than 1 day to 1 week. The total duration of the N-of-1 trial protocols ranged from 2 days to 28 weeks. Two studies had adaptive protocols that allowed for clinician-directed changes in dosing as part of the protocol 28, 30 ; dosages could be increased or decreased at the discretion of the treating physician who was blinded to treatment assignment. In another study, the N-of-1 trial protocol could be stopped early if participants met remission criteria after a prior treatment dose. 32 All studies included randomization, although in 1 case, this was only with respect to the timing of the insertion of a sham treatment, but not the sequence of increasing doses. 32 In the other studies, randomization was at the level of treatment blocks with balanced sequences. Only 1 study provided details pertaining to randomization technique and treatment allocation. 32 Three studies involved at least 1 treatment repetition. In 1 study, a medication was repeated, but at different escalating doses. 32 
Depressive Symptom Measurement
In 2 studies, the measure for assessing depressive symptoms was clinician administered (Montgomery-Åsberg Depression Rating Scale) 31, 32 ; in 2 studies, the depression measure was patient reported (Hopkins Symptoms Checklist-depression subscale), 29, 30 mood visual analog scale [VAS] created by the investigators); and in 1 study, a combination of patient-and clinician-administered scales was used (patient-and psychiatrist-administered global drug effect VAS scales and psychiatrist-administered Hamilton Depression Rating Scale). 30 All studies assessed treatment adverse effects, although the method for doing so was unclear in 1 study.
Analytic Approach
Quantitative approaches were used to assess for significant interindividual differences in treatment response in 2 studies. One used a 1-sided paired Student t test with an α = 0.1 to denote significant difference, and the other used the autoregressive integrated moving average method that accounts for autocorrelations in time-series data to compare differences across treatment periods. 30, 31 The remaining studies used cutpoints denoting treatment response or remission to determine individual treatment response but did not use statistical tests of significance to compare individual-level treatment effects.
Dropouts and Compliance
There were no dropouts in 3 studies 28, 29, 31 ; however, these studies were all conducted in monitored settings (nursing home, foster home, and inpatient). In 1 study of self-administered oral medication, 8 of 10 patients completed the study protocol, with 1 patient dropping out early because of perception of clear benefit on active treatment and 1 patient withdrawing after 13 weeks. 30 In the remaining study, 9 of 15 patients completed the study protocol, with 6 dropping out prematurely, all of whom had not obtained treatment benefit on the initial dose. 32 The 3 studies that involved self-administered medications did not include a medication adherence check.
N-of-1 Trial Findings
In all 4 studies that enrolled more than 1 patient, the investigators confirmed that there were individual-level differences in treatment responses that supported the use of the N-of-1 trial approach (Fig. 3) . In the ketamine dosing study, the investigators learned that participants responded to treatment at a range of doses from 0.1 mg/kg to 0.4 mg/kg. In the study of depressed geriatric patients, 2 of the 3 participants responded to methylphenidate. 32 In the study of depressed inpatients, the investigators learned that 5 participants responded to methylphenidate and D-amphetamine, 1 responded to neither, 7 responded to D-amphetamine, and 5 responded to methylphenidate. 29 In the study of treatment-resistant depressed outpatients, 7 of 8 participants responded to sulpiride versus placebo in at least 1 of 2 treatment periods, but only 3 of 8 participants responded to sulpiride in both treatment periods. 30 Finally, in the study with a single patient, the investigators learned that the active medication was superior to placebo. 28 No trials reported on clinician or patient satisfaction with N-of-1 trial design or included a comparison of the N-of-1 trial approach versus usual care.
Quality Rating
None of the studies was rated as high quality according to CONSORT-CENT Extension. The study that came closest to being a high-quality N-of-1 trial was the one by Maier and Benkert, 30 which included careful consideration of the requisite time blocks needed (ie, sample size) in terms of individual-level measurements and sequence repetition and used a rigorous statistical approach to compare treatment effects that accounted for autocorrelation in time-series data. Two studies did not include any repetitions of treatment and hence did not meet the minimal requirements for an N-of-1 trial according to some definitions. 16 
DISCUSSION
Through this systematic review, we aimed to understand the conditions under which N-of-1 trials could be feasible for personalizing depression treatment selection in clinical settings. Accordingly, we identified the range of treatments compared in published N-of-1 trials, the types of populations studied, the methodologies used to gather data, patient acceptability and compliance, and perceived helpfulness to patients and their clinicians. This systematic review demonstrated that it is possible to use the N-of-1 trial approach to personalize the selection of depression treatments in diverse contexts. N-of-1 trials were feasible both in monitored settings where treatments and outcome assessments were administered by clinicians and in outpatient settings where medications and outcome assessments were self-administered. Two of the published studies included patients who would have been likely to be excluded from conventional RCTs. This suggests that N-of-1 trials may be particularly well suited to evaluating treatments in patients with multiple comorbid health conditions who lack evidence on the effects of treatment in patients like them. Although the included trials demonstrated that N-of-1 trials are a potentially useful methodology, none of them provided details on implementation challenges such as cost, time, willingness of patients to participate, and perceived usefulness of the methodology to patients and clinicians. These challenges have limited the uptake of N-of-1 trials in clinical practice. medication (sulpiride) with duration of onset and washout more similar to second-generation antidepressant medications. 30 This suggests that there is potential for expanding N-of-1 trials to compare more commonly used first-line antidepressant medications with similar pharmacodynamics properties.
All of the trials sought to double-blind the treatments. In the case of the trial of ketamine, the investigators additionally sought to mask the control by using a sham treatment (midazolam). Of note, there is debate in the field of N-of-1 trials as to the necessity of blinding treatments. Some argue that if the goal is to learn about the best treatment for a single patient, then blinding may be counterproductive as expectancy effects are an important part of the total treatment effect for an individual patient. 37 Further, in a recent study that surveyed patients with chronic diseases about attitudes toward N-of-1 trials, patients disliked the notion of blinding treatments. 38 The special packaging and compounding required of blinding medications can also be costly, limiting the feasibility of broadly incorporating N-of-1 trials into clinical practice. In contrast, if the goal of the N-of-1 trial is to isolate the biological effect of an active treatment to a placebo, then blinding will likely be necessary. Ultimately, the decision to blind treatments tested in future N-of-1 trials for depression will depend on the goal of the N-of-1 trialist. While behavioral and psychological treatments were not tested in any of the studies in this review, it is worth highlighting that it is not possible to blind patients receiving such treatments.
The published N-of-1 trials primarily tested off-label or second-line medication treatments that lacked robust data from conventional RCTs. No trials tested complementary and alternative medicine treatments (eg, bright light therapy). Given the rationale of using N-of-1 trials to test treatments that lack conventional RCT evidence, complementary and alternative medicine may be a useful class of depression treatments to consider for testing in future N-of-1 trials. 39 None of the published N-of-1 trials tested psychological or other behavioral approaches to treating depression (eg, exercise). In the case of psychological therapies, this was likely due to the presumed lack of reversibility of psychotherapy. Nevertheless, the lack of prior published studies does not negate the potential for psychological therapies to be tested through N-of-1 trials. Although many psychological therapies are designed to be insight oriented and irreversible, there is evidence that the effects of psychological therapies wane if not maintained. Thus, one could imagine designing N-of-1 trials that compared brief psychological interventions or different maintenance strategies over time. While we found no examples of such behavioral therapies tested in N-of-1 trials for depression, such approaches have been tested in N-of-1 trials for other conditions. 40, 41 Only one of the included trials compared treatment effects using robust time-series analyses that account for autocorrelations between treatment effects across time. 30 There are now robust statistical techniques that future N-of-1 trialists can apply to their studies. 19 To make such analyses convenient for use in clinical practice, algorithms may be needed to automate these analyses. Future N-of-1 trials will have to think carefully about how to convey the understanding of these analyses to patients so that they can meaningfully impact on shared decision making.
There were some important limitations of this review. It is possible that N-of-1 trials were being conducted in clinical settings without publication of data or IRB review. Only 1 study was conducted in the era of smartphones and mobile health devices, and these devices were not incorporated into the study design. 32 In the current era, there may be new opportunities for more robust N-of-1 trials of antidepressant treatments with increased data collection enabled by the use of these technological innovations. 38 Finally, the overall conduct and reporting of these published N-of-1 trials did not meet the high-quality standards outlined by the CONSORT-CENT Extension guidelines. However, these studies were all conducted prior to the publication of these N-of-1 reporting guidelines.
The current evidence suggests that there is potential for N-of-1 trials to be suitable for personalizing depression treatment. Yet, there remains a need for additional studies of N-of-1 trials relevant to depression, including studies that compare the N-of-1 approach with usual care, incorporate measures of patient and clinician satisfaction, and consider issues such as cost-effectiveness and time burden. Developing and sharing methods for conducting N-of-1 trial protocols using mobile health tools may engender progress in this field. Additional questions to be addressed by the field are the necessity for blinding and randomization of treatments, as well as the necessity of multiple crossovers to reduce the potential for a biased understanding of treatment effects. Nevertheless, with advances in mobile health technology and growing interest in personalized treatment selection, these prior successful albeit flawed N-of-1 trials suggest that there may now be new opportunities to design and test N-of-1 trials for depression.
